No association between increased prolactin levels and progression of left ventricular mass in German cohort study

2008 ◽  
Vol 116 (09) ◽  
Author(s):  
A Steveling ◽  
R Haring ◽  
SB Felix ◽  
M Nauck ◽  
M Dörr ◽  
...  
Keyword(s):  
Cohort Study ◽  
Left Ventricular Mass ◽  
Left Ventricular ◽  
Ventricular Mass

scholarly journals HIV Infection Is Associated with Greater Left Ventricular Mass in the Multicenter AIDS Cohort Study

2019 ◽  
Vol 35 (8) ◽  
pp. 755-761
Author(s):  
Elizabeth Hutchins ◽  
Ruibin Wang ◽  
Sina Rahmani ◽  
Rine Nakanishi ◽  
Sabina Haberlen ◽  
...  
Keyword(s):  
Cohort Study ◽  
Hiv Infection ◽  
Left Ventricular Mass ◽  
Left Ventricular ◽  
Multicenter Aids Cohort Study ◽  
Ventricular Mass

scholarly journals Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

2018 ◽  
Vol 55 (5) ◽  
pp. 351-358 ◽  
Author(s):  
Maarten Arends ◽  
Marieke Biegstraaten ◽  
Christoph Wanner ◽  
Sandra Sirrs ◽  
Atul Mehta ◽  
...  
Keyword(s):  
Cohort Study ◽  
Fabry Disease ◽  
Left Ventricular Mass ◽  
Event Rate ◽  
Left Ventricular ◽  
Clinical Event ◽  
Agalsidase Beta ◽  
Enzyme Replacement ◽  
Agalsidase Alfa ◽  
Ventricular Mass

BackgroundTwo recombinant enzymes (agalsidase alfa 0.2 mg/kg/every other week and agalsidase beta 1.0 mg/kg/every other week) have been registered for the treatment of Fabry disease (FD), at equal high costs. An independent international initiative compared clinical and biochemical outcomes of the two enzymes.MethodsIn this multicentre retrospective cohort study, clinical event rate, left ventricular mass index (LVMI), estimated glomerular filtration rate (eGFR), antibody formation and globotriaosylsphingosine (lysoGb3) levels were compared between patients with FD treated with agalsidase alfa and beta at their registered dose after correction for phenotype and sex.Results387 patients (192 women) were included, 248 patients received agalsidase alfa. Mean age at start of enzyme replacement therapy was 46 (±15) years. Propensity score matched analysis revealed a similar event rate for both enzymes (HR 0.96, P=0.87). The decrease in plasma lysoGb3 was more robust following treatment with agalsidase beta, specifically in men with classical FD (β: −18 nmol/L, P<0.001), persisting in the presence of antibodies. The risk to develop antibodies was higher for patients treated with agalsidase beta (OR 2.8, P=0.04). LVMI decreased in a higher proportion following the first year of agalsidase beta treatment (OR 2.27, P=0.03), while eGFR slopes were similar.ConclusionsTreatment with agalsidase beta at higher dose compared with agalsidase alfa does not result in a difference in clinical events, which occurred especially in those with more advanced disease. A greater biochemical response, also in the presence of antibodies, and better reduction in left ventricular mass was observed with agalsidase beta.

scholarly journals Midlife blood pressure change and left ventricular mass and remodelling in older age in the 1946 British birth cohort study†

2014 ◽  
Vol 35 (46) ◽  
pp. 3287-3295 ◽  
Author(s):  
Arjun K. Ghosh ◽  
Rebecca J. Hardy ◽  
Darrel P. Francis ◽  
Nishi Chaturvedi ◽  
Denis Pellerin ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cohort Study ◽  
Birth Cohort ◽  
Left Ventricular Mass ◽  
Pressure Change ◽  
Left Ventricular ◽  
Older Age ◽  
Blood Pressure Change ◽  
Birth Cohort Study ◽  
Ventricular Mass

HIV INFECTION IS ASSOCIATED WITH INCREASED LEFT VENTRICULAR MASS IN THE MULTICENTER AIDS COHORT STUDY (MACS)

2018 ◽  
Vol 71 (11) ◽  
pp. A909
Author(s):  
Elizabeth Hutchins ◽  
Ruibin Wang ◽  
Sina Rahmani ◽  
Rine Nakanishi ◽  
Mallory Witt ◽  
...  
Keyword(s):  
Cohort Study ◽  
Hiv Infection ◽  
Left Ventricular Mass ◽  
Left Ventricular ◽  
Multicenter Aids Cohort Study ◽  
Ventricular Mass

Abstract #330: Insulin Resistance, Cardiac Output and Left Ventricular Mass in Different Degrees of Obesity

2006 ◽  
Vol 12 ◽  
pp. 6-7
Author(s):  
Juan Ybarra ◽  
Josep Maria Pou ◽  
Teresa Doñate ◽  
Monica Isart ◽  
Jaime Pujadas
Keyword(s):  
Insulin Resistance ◽  
Cardiac Output ◽  
Left Ventricular Mass ◽  
Left Ventricular ◽  
Ventricular Mass

The association of ankle brachial index with left ventricular hypertrophy and left ventricular mass index: the Dong-gu study

VASA ◽  
2013 ◽  
Vol 42 (4) ◽  
pp. 284-291 ◽  
Author(s):  
Seong-Woo Choi ◽  
Hye-Yeon Kim ◽  
Hye-Ran Ahn ◽  
Young-Hoon Lee ◽  
Sun-Seog Kweon ◽  
...  
Keyword(s):  
Left Ventricular Hypertrophy ◽  
Left Ventricular Mass ◽  
Ventricular Hypertrophy ◽  
Left Ventricular Mass Index ◽  
Ankle Brachial Index ◽  
Intima Media Thickness ◽  
Left Ventricular ◽  
Baseline Survey ◽  
Ventricular Mass Index ◽  
Ventricular Mass

Background: To investigate the association between ankle-brachial index (ABI), left ventricular hypertrophy (LVH) and left ventricular mass index (LVMI) in a general population. Patients and methods: The study population consisted of 8,246 people aged 50 years and older who participated in the baseline survey of the Dong-gu Study conducted in Korea between 2007 and 2010. Trained research technicians measured LV mass using mode M ultrasound echocardiography and ABI using an oscillometric method. Results: After adjustment for risk factors and common carotid artery intima-media thickness (CCA-IMT) and the number of plaques, higher ABIs (1.10 1.19, 1.20 - 1.29, and ≥ 1.30) were significantly and linearly associated with high LVMI (1.10 - 1.19 ABI: β, 3.33; 95 % CI, 1.72 - 4.93; 1.20 - 1.29 ABI: β, 6.51; 95 % CI, 4.02 - 9.00; ≥ 1.30 ABI: β, 14.83; 95 % CI, 6.18 - 23.48). An ABI of 1.10 - 1.19 and 1.20 - 1.29 ABI was significantly associated with LVH (1.10 - 1.19 ABI: OR, 1.35; 95 % CI, 1.19 - 1.53; 1.20 - 1.29 ABI: OR, 1.59; 95 % CI, 1.31 - 1.92) and ABI ≥ 1.30 was marginally associated with LVH (OR, 1.73; 95 % CI, 0.93 - 3.22, p = 0.078). Conclusions: After adjustment for other cardiovascular variables and CCA-IMT and the number of plaques, higher ABIs are associated with LVH and LVMI in Koreans aged 50 years and older.

Sign in / Sign up

Export Citation Format

Share Document